These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19553638)

  • 61. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia.
    Frey UH; Nückel H; Sellmann L; Siemer D; Küppers R; Dürig J; Dührsen U; Siffert W
    Clin Cancer Res; 2006 Oct; 12(19):5686-92. PubMed ID: 17020971
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S132-8. PubMed ID: 22226097
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
    Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.
    Dreger P; Michallet M; Schmitz N
    Ann Oncol; 2000; 11 Suppl 1():49-53. PubMed ID: 10707779
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria.
    Madu AJ; Korubo K; Okoye A; Ajuba I; Duru AN; Ugwu AO; Nnachi O; Okoye HC
    Malawi Med J; 2019 Jun; 31(2):144-149. PubMed ID: 31452848
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.
    Maffei R; Martinelli S; Santachiara R; Rossi D; Guarnotta C; Sozzi E; Zucchetto A; Rigolin GM; Fiorcari S; Castelli I; Fontana M; Coluccio V; Leonardi G; Zucchini P; Tripodo C; Cuneo A; Gattei V; Del Poeta G; Forconi F; Gaidano G; Torelli G; Marasca R
    Blood; 2010 Jul; 116(4):584-92. PubMed ID: 20382847
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases.
    Cartron G; Linassier C; Bremond JL; Desablens B; Georget MT; Fimbel B; Luthier F; Dutel JL; Lamagnere JP; Colombat P
    Leuk Lymphoma; 1998 Sep; 31(1-2):209-16. PubMed ID: 9720730
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia.
    Miao Y; Fan L; Wu YJ; Xia Y; Qiao C; Wang Y; Wang L; Hong M; Zhu HY; Xu W; Li JY
    Oncotarget; 2016 Mar; 7(12):13551-62. PubMed ID: 26910908
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.
    Falchi L; Vitale C; Keating MJ; Lerner S; Wang X; Elhor Gbito KY; Strom S; Wierda WG; Ferrajoli A
    Ann Oncol; 2016 Jun; 27(6):1100-1106. PubMed ID: 26912560
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?
    Visco C; Cortelezzi A; Moretta F; Falisi E; Maura F; Finotto S; Barcellini W; Ambrosetti A; Neri A; Ruggeri M; Rodeghiero F
    Leuk Lymphoma; 2014 Jun; 55(6):1261-5. PubMed ID: 24047107
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century.
    Pulte D; Castro FA; Jansen L; Luttmann S; Holleczek B; Nennecke A; Ressing M; Katalinic A; Brenner H;
    J Hematol Oncol; 2016 Mar; 9():28. PubMed ID: 27000264
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
    van Gelder M; de Wreede LC; Bornhäuser M; Niederwieser D; Karas M; Anderson NS; Gramatzki M; Dreger P; Michallet M; Petersen E; Bunjes D; Potter M; Beelen D; Cornelissen JJ; Yakoub-Agha I; Russell NH; Finke J; Schoemans H; Vitek A; Urbano-Ispízua Á; Blaise D; Volin L; Chevallier P; Caballero D; Putter H; van Biezen A; Henseler A; Schönland S; Kröger N; Schetelig J
    Bone Marrow Transplant; 2017 Mar; 52(3):372-380. PubMed ID: 27941763
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.
    Thurmes P; Call T; Slager S; Zent C; Jenkins G; Schwager S; Bowen D; Kay N; Shanafelt T
    Leuk Lymphoma; 2008 Jan; 49(1):49-56. PubMed ID: 18203011
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Alrawashdh N; Sweasy J; Erstad B; McBride A; Persky DO; Abraham I
    Ann Hematol; 2021 Oct; 100(10):2501-2512. PubMed ID: 34279676
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Primary care management of early stage chronic lymphocytic leukaemia is safe and effective.
    Parry HM; Damery S; Mudondo NP; Hazlewood P; McSkeane T; Aung S; Murray J; Pratt G; Moss P; Milligan DW
    QJM; 2015 Oct; 108(10):789-94. PubMed ID: 25638788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chronic lymphocytic leukaemia: a-twenty-years experience and problems in Ile-Ife, South-Western Nigeria.
    Salawu L; Bolarinwa RA; Durosinmi MA
    Afr Health Sci; 2010 Jun; 10(2):187-92. PubMed ID: 21326974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.